At its meeting on 17 June 2024, the Transparency Council adopted position No. 57/2024 on the evaluation of the drug Vesoxx (oxybutynini hydrochloridum) under the drug program “Treatment of patients with neurogenic detrusor overreactivity (ICD-10: N31)”.